Sanofi's decision not to opt-in to the development and commercialization of ultra-orphan therapy lumasiran is considered a positive for the product's originator, Alnylam Pharmaceuticals Inc., but there are concerns that the French firm has now declined options on several of Alnylam's investigational RNA interference (RNAi) products that might have supported the biotech as it prepares its strategy for the potential approval and launch of lead product, patisiran, for the treatment of hereditary ATTR amyloidosis, in mid-2018.
Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive
Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.